3 ms·

So the long term risks are mostly from secondary infection, and it's only half of the 5-11% of the cases of mortality after treatment. I think that sounds pret

So the long term risks are mostly from secondary infection, and it's only half of the 5-11% of the cases of mortality after treatment. I think that sounds pretty fucking good considering the other option is definitely just being dead. That's as close to a miracle treatment as I believe we will get.

amluto 2y ago
If you’re treating an otherwise-fatal cancer, sure, although it would still great to further improve the treatment. If you’re treating a much less lethal autoimmune condition, then the calculation is a bit different.